A recombinant adenovirus vaccine against the SARS Coronavirus (SARS-CoV) was constructed, which contains fragments from the S, N, and Orf8 genes. Rhesus Macaques immunized with the recombinant adenovirus generated antigen-specific humoral and cellular response. Furthermore, the vaccine provided significant protection against subsequent live SARS-CoV challenge. In contrast, three out of four monkeys immunized with placebo suffered severe alveolar damage and pulmonary destruction. The SARS-CoV is a novel coronavirus first identified in 2003 1,2 , which causes severe respiratory distress in patients and can be lethal, especially in people over 65 years old.
quickly after the booster injection (Figure 1a) . By week 8, all immunized monkeys produced high titers of IgG antibody whereas animals in the placebo group only had baseline level. Neutralizing antibody followed similar trend with the high-dose and lowdose group reaching titers of 95+/-65and 83+/-38, respectively (Figure 1b) .
In order to test whether the recombinant adenovirus can illicit antigen-specific T cell response, pools of overlapping peptides corresponding to target antigen sequences were used to stimulate PBMCs harvested from monkeys four weeks after the booster injection. Animals from immunized groups generated detectable IFN- response (Figure   1c ), whereas the placebo group did not show any significant response above background. Furthermore, peptides from both pools were able to induce IFN- release from immunized samples, indicating that both genes were expressed in vivo and were recognized by the immune system. Interestingly, the highest T cell response came from monkey #0195 in the low-dose group, which had at least10-times higher response than any other animal.
To test the protective efficacy of the recombinant adenovirus vaccine, monkeys in the high-dose, low-dose, and placebo group were challenged intranasally with 10 5 TCID50 live virus of the PUMC-1 strain (Genbank Accession No. AY350750). Two additional uninfected monkeys housed in the same facility were used as negative control. Three days after virus inoculation, monkeys in the placebo group became lethargic, and had markedly reduced food intake (Figure 1d) . Two animals displayed respiratory distress, including shortness of breath and increased respiratory rate. In contrast, none of the immunized animals, or the control animals, displayed any visible respiratory stress during the entire period of the experiment.
Pharyngeal swab and serum samples were collected on day 2, 5, and 7 after challenge. The presence of SARS-CoV was detected via either RT-PCR or viral culture ( Table 1) . Three out of eight immunized animals had detectable RNA, and only one of which was positive on day 7. In contrast, viral RNA could be detected in all four animals in the placebo group, and it persisted for at least 5 days. The absolute viral load also appeared to be significantly higher than that of the immunized animals.
Pharyngeal swab samples were also used to inoculate Vero cells in order to reisolate live virus after the challenge. Infectious viral particles can be isolated from four out of eight animals in the immunized animals, and only one of which had active viral replication by day 5. In contrast, infectious viral particles can be isolated from three out of four animals in the placebo group, two of which had active viral replication by day 5.
Postmortem tissues, including serum, lung, kidney, spleen, liver, and lymph node, were also analyzed, and no positive culture could be identified in any sample. As expected, no infectious viral particles can be isolated from the control animals. In order to correlate the disease pathology with viral replication in situ, sections of the lung were also analyzed by immunohistochemistry. There was minimal, if any, staining in the sections for the high-dose group (Figure 2e) , which was similar to that of control (Figure 2d) . In contrast, sections for the placebo group showed numerous positive cells, with predominantly cytosolic staining, indicating continuing antigen expression in these cells (Figure 2f) . The low-dose group also had significant antigen present within the alveoli wall and the epithelial cells (Supplemental Figure 2d) .
Despite of recent advances, the development of an effective vaccine for SARS-
CoV is likely to encounter significant hurdles in the future. One potential roadblock is the emergence of viral mutations 7 . The PUMC-1 strain differs from the BJ01 strain in two positions within the S1 domain (G->D on position 21,721, and I->T on position 22,222). It was speculated that these two sites might be involved in a viral escape mechanism, since all the hotel M associated cases carry D and T whereas other cases in Northern China had G and I, respectively 8, 9 . Inclusion of multiple target genes in the vaccine design can potentially reduce the likelihood of viral escape.
Here we have shown that Rhesus Macaques immunized with SV8000, especially those in the high-dose group, had lower viral load, shorter viral persistence period, less severe pathological damages, and importantly almost no visible respiratory stress symptoms. All the data collectively demonstrated the validity of using a recombinant adenovirus vaccine to prevent SARS-CoV infection, and further clinical evaluation in human is warranted. Table 1 Group ID NAb titer day 2 day 5 day 7 day 2 day 5 day 7  0176  128  +  --114  --0164  32  +  --151  --0173  177  -----high-dose 0095  44  ------R0162  51  +  +  ----0138  102  +  -----0105  128  -----7 5  low-dose 0195  51  ------0162  2  ---113  4034  108  0058  2  +  ---72  -0127  2  +  +  -131  717  placebo  0155  2  +  +  +  270  161  4101  0096  2  -----control  0055  2  ------ cytopathic effect virus copy number 
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